As announced on June 9, 2022, Partner Adam Finerman and BakerHostetler represented Pulse Biosciences Inc. in a public rights offering pursuant to which Pulse sold more than 7 million units for an aggregate of more than $15 million, with each unit consisting of one share and one warrant to purchase a share. Pulse Biosciences is a bioelectric medicine company commercializing its CellFX® System, powered by Pulse’s proprietary Nano-Pulse Stimulation™. Initial commercial use of the CellFX System has been in dermatologic conditions.
More information